Court sides with FDA in Vanda clinical hold suit
The US District Court for the District of Columbia on Friday ruled in the FDA’s favor in a case brought by Vanda Pharmaceuticals concerning a partial clinical hold placed on a study of the company’s investigational drug tradipitant in December 2018.
In the decision, Judge John Bates denied Vanda’s motions for summary judgement and refused to allow the filing of an amicus brief by the Humane Society that challenged the FDA’s justification for an additional animal study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.